

## NA Thyroid Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2023-01-01 | 217 pages | Data Bridge Market Research

#### **AVAILABLE LICENSES:**

- Single User License \$3500.00
- Corporate Users License \$4200.00

#### Report description:

The North America thyroid cancer diagnostics market is projected to register a substantial CAGR of 6.4% from 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030

#### Market Segmentation:

North America Thyroid Cancer Diagnostics Market, By Product Type (Instruments, Consumables & Accessories), Test Type (Imaging Test, Blood Test, Biopsy, Others), Cancer Type (Papillary Carcinoma, Follicular Carcinoma, Others), Stages (Stage I, Stage II, Stage III, Stage IV), Age Group (30-65, 65 and above, 21-29, Below 21), End User (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Others), Distribution Channel (Direct Tender, Retail Sales), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2030

Some of the major factors contributing to the growth of the North America thyroid cancer diagnostics market are:

- Rising incidence and prevalence of thyroid nodules & cancer
- Rising thyroid cancer diagnostic tests rise in product approvals
- Rising awareness towards thyroid cancer

#### Market Players:

Some major companies which are dealing in the North America thyroid cancer diagnostics market are listed below:

- Canon Inc.
- FUJIFILM Holdings Corporation
- F. Hoffmann-La Roche Ltd
- Quest Diagnostics Incorporated
- Illumina
- Koninklijke Philips N.V.
- Thermo Fisher Scientific Inc.
- Siemens Healthcare GmbH
- Abbott
- General Electric Company

Scotts International. EU Vat number: PL 6772247784

- QIAGEN
- DIASORIN S.P.A.
- Merck KGaA
- Hologic
- Myriad Genetics Inc.
- BIOMERIEUX
- FONAR Corp.
- Time Medical Holding.
- MinFound Medical Systems Co., Ltd

#### **Table of Contents:**

TABLE OF CONTENTS

- 1 INTRODUCTION 46
- 1.1 OBJECTIVES OF THE STUDY 46
- 1.2 MARKET DEFINITION 46
- 1.3 OVERVIEW OF THE NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET 46
- 1.4 LIMITATIONS 48
- 1.5 MARKETS COVERED 48
- 2 MARKET SEGMENTATION 51
- 2.1 MARKETS COVERED 51
- 2.2 GEOGRAPHICAL SCOPE 52
- 2.3 YEARS CONSIDERED FOR THE STUDY 53
- 2.4 CURRENCY AND PRICING 53
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL 54
- 2.6 MULTIVARIATE MODELLING 57
- 2.7 PRODUCT TYPE LIFELINE CURVE 57
- 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 58
- 2.9 DBMR MARKET POSITION GRID 59
- 2.10 MARKET TESTING TYPE COVERAGE GRID 61
- 2.11 VENDOR SHARE ANALYSIS 62
- 2.12 SECONDARY SOURCES 63
- 2.13 ASSUMPTIONS 63
- 3 EXECUTIVE SUMMARY 64
- 4 PREMIUM INSIGHTS 67
- 4.1 PESTEL ANALYSIS 68
- 4.2 PORTER'S FIVE FORCES 69
- 4.3 GROWTH STRATEGIES ADOPTED BY KEY MARKET PLAYERS 70
- 5 EPIDEMIOLOGY 71
- 6 REGULATORY FRAMEWORK OF THE NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET 72

Page 2/8

- 6.1 REGULATORY SCENARIO IN THE U.S. 72
- 6.2 REGULATORY SCENARIO IN AUSTRALIA 73
- 6.3 REGULATORY SCENARIO IN JAPAN 73
- 6.4 REGULATORY SCENARIO IN CHINA 73
- 7 MARKET OVERVIEW 74
- 7.1 DRIVERS 76

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

- 7.1.1 RISING INCIDENCE AND PREVALENCE OF THYROID NODULES AND CANCER 76
- 7.1.2 RISING THYROID CANCER DIAGNOSTIC TESTS 76
- 7.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 77
- 7.1.4 RISING AWARENESS TOWARDS THYROID CANCER 77
- 7.2 RESTRAINTS 78
- 7.2.1 HIGH COST OF DIAGNOSTICS PROCEDURE 78
- 7.2.2 TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS 79
- 7.3 OPPORTUNITIES 79
- 7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 79
- 7.3.2 RISING OBESE POPULATION 80
- 7.4 CHALLENGES 80
- 7.4.1 STRINGENT REGULATORY FRAMEWORK FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS
- 7.4.2 LACK OF SKILLED AND CERTIFIED EXPERTISE 81
- 8 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 82
- 8.1 OVERVIEW 83
- 8.2 INSTRUMENTS 86
- 8.2.1 PATHOLOGY BASED INSTRUMENTS 87
- 8.2.1.1 PCR INSTRUMENTS 87
- 8.2.1.2 SLIDE STAINING SYSTEMS 87
- 8.2.1.3 TISSUE PROCESSING SYSTEMS 87
- 8.2.1.4 CELL PROCESSORS 88
- 8.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS 88
- 8.2.2 IMAGING INSTRUMENTS 88
- 8.2.2.1 ULTRASOUND SYSTEMS 88
- 8.2.2.2 CT SYSTEMS 88
- 8.2.2.3 MRI SYSTEMS 88
- 8.2.2.4 OTHERS 88
- 8.2.3 BIOPSY INSTRUMENTS 89
- 8.2.3.1 NEEDLE BIOPSY 89
- 8.2.3.2 ENDOSCOPIC BIOPSY 89
- 8.2.3.3 CORE BIOPSY 89
- 8.2.3.4 OTHERS 89
- 8.2.4 OTHERS 89
- 8.3 CONSUMABLES & ACCESSORIES 90
- 8.3.1 KITS 91
- 8.3.1.1 PCR KITS 91
- 8.3.1.2 DNA POLYMERASE KITS 91
- 8.3.1.3 NUCLEIC ACID ISOLATION KITS 91
- 8.3.1.4 OTHERS 91
- 8.3.2 REAGENTS 92
- 8.3.2.1 ASSAYS 92
- 8.3.2.2 BUFFERS 92
- 8.3.2.3 PRIMERS 92
- 8.3.2.4 OTHERS 92
- 8.3.3 PROBES 92
- 8.3.4 OTHER CONSUMABLES 92

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE 93
- 9.1 OVERVIEW 94
- 9.2 IMAGING TEST 97
- 9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 98
- 9.2.2 MRI 98
- 9.2.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 98
- 9.2.4 OTHERS 98
- 9.3 BLOOD TEST 99
- 9.3.1 BLOOD CHEMISTRY TESTS 100
- 9.3.2 COMPLETE BLOOD COUNT (CBC) 100
- 9.3.3 OTHERS 100
- 9.4 BIOPSY 100
- 9.4.1 NEEDLE BIOPSY 101
- 9.4.2 BRONCHOSCOPY BIOPSY 101
- 9.4.3 CORE BIOPSY 101
- 9.4.4 OTHERS 101
- 9.5 OTHERS 102
- 10 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 103
- 10.1 OVERVIEW 104
- 10.2 PAPILLARY CARCINOMA 107
- 10.3 FOLLICULAR CARCINOMA 108
- 10.4 OTHERS 109
- 11 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY STAGES 110
- 11.1 OVERVIEW 111
- 11.2 STAGE I 114
- 11.3 STAGE II 115
- 11.4 STAGE III 116
- 11.5 STAGE IV 117
- 12 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP 118
- 12.1 OVERVIEW 119
- 12.2 30-65 122
- 12.3 65 AND ABOVE 123
- 12.4 21-29 124
- 12.5 BELOW 21 125
- 13 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY END USER 126
- 13.1 OVERVIEW 127
- 13.2 HOSPITALS 130
- 13.3 ASSOCIATED LABS 131
- 13.4 INDEPENDENT DIAGNOSTIC LABORATORIES 131
- 13.5 DIAGNOSTIC IMAGING CENTERS 132
- 13.6 CANCER RESEARCH INSTITUTES 133
- 13.7 OTHERS 134
- 14 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 135
- 14.1 OVERVIEW 136
- 14.2 DIRECT TENDER 139
- 14.3 RETAIL SALES 140
- 15 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY REGION 141

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.1 NORTH AMERICA 142
- 15.1.1 U.S. 152
- 15.1.2 CANADA 157
- 15.1.3 MEXICO 162
- 16 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 167
- 16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 167
- 17 SWOT ANALYSIS 168
- 18 COMPANY PROFILE 169
- 18.1 CANON INC. 169
- 18.1.1 COMPANY SNAPSHOT 169
- 18.1.2 COMPANY SHARE ANALYSIS 169
- 18.1.3 PRODUCT PORTFOLIO 170
- 18.1.4 RECENT DEVELOPMENTS 170
- 18.2 FUIIFILM CORPORATION 171
- 18.2.1 COMPANY SNAPSHOT 171
- 18.2.2 REVENUE ANALYSIS 171
- 18.2.3 COMPANY SHARE ANALYSIS 172
- 18.2.4 PRODUCT PORTFOLIO 172
- 18.2.5 RECENT DEVELOPMENT 172
- 18.3 F. HOFFMANN-LA ROCHE LTD 173
- 18.3.1 COMPANY SNAPSHOT 173
- 18.3.2 REVENUE ANALYSIS 173
- 18.3.3 COMPANY SHARE ANALYSIS 174
- 18.3.4 PRODUCT PORTFOLIO 174
- 18.3.5 RECENT DEVELOPMENT 174
- 18.4 QUEST DIAGNOSTICS INCORPORATED 175
- 18.4.1 COMPANY SNAPSHOT 175
- 18.4.2 REVENUE ANALYSIS 175
- 18.4.3 COMPANY SHARE ANALYSIS 176
- 18.4.4 PRODUCT PORTFOLIO 176
- 18.4.5 RECENT DEVELOPMENTS 176
- 18.5 ILLUMINA, INC. 178
- 18.5.1 COMPANY SNAPSHOT 178
- 18.5.2 REVENUE ANALYSIS 178
- 18.5.3 COMPANY SHARE ANALYSIS 179
- 18.5.4 PRODUCT PORTFOLIO 179
- 18.5.5 RECENT DEVELOPMENT 179
- 18.6 ABBOTT 180
- 18.6.1 COMPANY SNAPSHOT 180
- 18.6.2 REVENUE ANALYSIS 180
- 18.6.3 PRODUCT PORTFOLIO 181
- 18.6.4 RECENT DEVELOPMENT 181
- 18.7 BD 182
- 18.7.1 COMPANY SNAPSHOT 182
- 18.7.2 REVENUE ANALYSIS 182
- 18.7.3 PRODUCT PORTFOLIO 183
- 18.7.4 RECENT DEVELOPMENT 183

- 18.8 BEIJING O&D BIOTECH CO., LTD. 184
- 18.8.1 COMPANY SNAPSHOT 184
- 18.8.2 PRODUCT PORTFOLIO 184
- 18.8.3 RECENT DEVELOPMENTS 184
- 18.9 BIOMERIEUX SA 185
- 18.9.1 COMPANY SNAPSHOT 185
- 18.9.2 REVENUE ANALYSIS 185
- 18.9.3 PRODUCT PORTFOLIO 186
- 18.9.4 RECENT DEVELOPMENTS 186
- 18.10 DIASORIN S.P.A. 187
- 18.10.1 COMPANY SNAPSHOT 187
- 18.10.2 REVENUE ANALYSIS 187
- 18.10.3 PRODUCT PORTFOLIO 188
- 18.10.4 RECENT DEVELOPMENT 188
- 18.11 FONAR CORP. 189
- 18.11.1 COMPANY SNAPSHOT 189
- 18.11.2 REVENUE ANALYSIS 189
- 18.11.3 PRODUCT PORTFOLIO 190
- 18.11.4 RECENT DEVELOPMENTS 190
- 18.12 GENERAL ELECTRIC 191
- 18.12.1 COMPANY SNAPSHOT 191
- 18.12.2 REVENUE ANALYSIS 191
- 18.12.3 PRODUCT PORTFOLIO 192
- 18.12.4 RECENT DEVELOPMENTS 192
- 18.13 HOLOGIC INC. 193
- 18.13.1 COMPANY SNAPSHOT 193
- 18.13.2 REVENUE ANALYSIS 193
- 18.13.3 PRODUCT PORTFOLIO 194
- 18.13.4 RECENT DEVELOPMENT 194
- 18.14 KONINKLIJKE PHILIPS N.V. 195
- 18.14.1 COMPANY SNAPSHOT 195
- 18.14.2 REVENUE ANALYSIS 195
- 18.14.3 PRODUCT PORTFOLIO 196
- 18.14.4 RECENT DEVELOPMENT 196
- 18.15 MERCK KGAA. 197
- 18.15.1 COMPANY SNAPSHOT 197
- 18.15.2 REVENUE ANALYSIS 197
- 18.15.3 PRODUCT PORTFOLIO 198
- 18.15.4 RECENT DEVELOPMENT 198
- 18.16 MEDONICA CO. LTD 199
- 18.16.1 COMPANY SNAPSHOT 199
- 18.16.2 PRODUCT PORTFOLIO 199
- 18.16.3 RECENT DEVELOPMENT 199
- 18.17 MINFOUND MEDICAL SYSTEMS CO. LTD 200
- 18.17.1 COMPANY SNAPSHOT 200
- 18.17.2 PRODUCT PORTFOLIO 200
- 18.17.3 RECENT DEVELOPMENTS 201

- 18.18 MYRIAD GENETICS, INC. 202
- 18.18.1 COMPANY SNAPSHOT 202
- 18.18.2 REVENUE ANALYSIS 202
- 18.18.3 PRODUCT PORTFOLIO 203
- 18.18.4 RECENT DEVELOPMENTS 203
- 18.19 PLEXBIO. 204
- 18.19.1 COMPANY SNAPSHOT 204
- 18.19.2 PRODUCT PORTFOLIO 204
- 18.19.3 RECENT DEVELOPMENTS 204
- 18.20 QIAGEN 205
- 18.20.1 COMPANY SNAPSHOT 205
- 18.20.2 REVENUE ANALYSIS 205
- 18.20.3 PRODUCT PORTFOLIO 206
- 18.20.4 RECENT DEVELOPMENT 206
- 18.21 STERNMED GMBH 207
- 18.21.1 COMPANY SNAPSHOT 207
- 18.21.2 PRODUCT PORTFOLIO 207
- 18.21.3 RECENT DEVELOPMENTS 207
- 18.22 SIEMENS HEALTHCARE GMBH 208
- 18.22.1 COMPANY SNAPSHOT 208
- 18.22.2 REVENUE ANALYSIS 208
- 18.22.3 PRODUCT PORTFOLIO 209
- 18,22,4 RECENT DEVELOPMENT 209
- 18.23 TIME MEDICAL HOLDING. 210
- 18.23.1 COMPANY SNAPSHOT 210
- 18.23.2 PRODUCT PORTFOLIO 210
- 18.23.3 RECENT DEVELOPMENT 210
- 18.24 THERMO FISHER SCIENTIFIC INC. 211
- 18.24.1 COMPANY SNAPSHOT 211
- 18.24.2 REVENUE ANALYSIS 211
- 18.24.3 PRODUCT PORTFOLIO 212
- 18.24.4 RECENT DEVELOPMENT 212
- 19 OUESTIONNAIRE 213



☐ - Print this form

To place an Order with Scotts International:

 $\hfill \Box$  - Complete the relevant blank fields and sign

# NA Thyroid Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2023-01-01 | 217 pages | Data Bridge Market Research

ORDER FORM:	Licence			Deiaa
Select license	License Single User License			Price \$3500.00
	Corporate Users License			\$4200.00
	Corporate Osers Electise			VAT
				Total
viii viii be daded e	at 23% for Polish based companies, in	idividuals and 20 basea (	companies who are unable to pre	viac a valia 20 ve
Email*		Phone*		
L r		Phone*  Last Name*		
irst Name*		<b>_</b>		
irst Name* [		<b>_</b>	/ NIP number*	
irst Name* [ ob title* [ Company Name* [		Last Name*	/ NIP number*	
Email*  First Name*  Ob title*  Company Name*  Address*  Zip Code*		Last Name*  EU Vat / Tax ID /	/ NIP number*	
First Name* [ ob title* [ Company Name* [ Address* [		Last Name*  EU Vat / Tax ID /  City*	/ NIP number*	
irst Name* [ ob title* [ Company Name* [ Address*		Last Name*  EU Vat / Tax ID /  City*  Country*		